BioArctic AB (OSTO:BIOA B)
kr 238.4 5 (2.14%) Market Cap: 21.06 Bil Enterprise Value: 20.57 Bil PE Ratio: 0 PB Ratio: 21.21 GF Score: 55/100

Q4 2021 BioArctic AB Earnings Call Transcript

Feb 03, 2022 / 08:30AM GMT
Release Date Price: kr110.2 (-1.25%)
Operator

Hello, and welcome to the BioArctic Audiocast for Teleconference Q4 2021. (Operator Instructions) Just to remind you, this conference call is being recorded.

Today, I am pleased to present CEO, Gunilla Osswald; and CFO, Jan Mattsson. Please go ahead with your meeting.

Gunilla Osswald;publ;CEO
BioArctic AB

()-

Thank you, and good morning, and welcome to BioArctic's full year report for 2021. I will also give some highlights from the fourth quarter. I'm Gunilla Osswald, and I'm the CEO of BioArtic, and I will share today's presentation with our CFO, Jan Mattsson.

It has been a great year for BioArctic and lecanemab, and it is time of hope for Alzheimer's patients. Lecanemab got fast track and breakthrough therapy designation by the FDA during the last year. And our partner Eisai has had interactions with the FDA. And after that, they have initiated a rolling submission, which is ongoing for an accelerated approval for lecanemab in the U.S.

I think that this year will be the most exciting year for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot